INVO Bioscience, Inc. - 8-K Filing Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by INVO Bioscience, Inc. (INVO) on November 8, 2021, reporting events occurring on November 2, 2021. The filing addresses the termination of a material definitive agreement with Ferring International Center S.A. ("Ferring") and the subsequent regaining of commercialization rights.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate events and contractual changes rather than financial performance data.
Material Changes
- Termination of Distribution Agreement: Ferring notified INVO on November 2, 2021, of its intention to terminate the Distribution Agreement dated November 12, 2018, for convenience. The agreement will officially terminate on January 31, 2022, following a 90-day notice period.
- Termination of Supply Agreement: The related Supply Agreement with Ferring automatically terminates concurrently with the Distribution Agreement on January 31, 2022.
- Regaining Rights: As a result of the termination, INVO is regaining full U.S. commercialization rights for its product.
- Transition Obligations: For 90 days post-termination, Ferring is required to use commercially reasonable efforts to transition customers to INVO and provide a list of existing customers.
Outlook, Risks, and Management Commentary
Management indicated that the termination allows INVO to regain full U.S. commercialization rights. The primary operational focus during the transition period (through January 31, 2022) will be the orderly transfer of distribution and customer relationships from Ferring to INVO or its designee. No specific financial guidance or new risk factors were disclosed in this filing beyond the execution of the transition.
Key Facts for Investor Verification
- Confirm the official termination date of the Ferring agreements is January 31, 2022.
- Verify the status of the customer transition process and the list of customers provided by Ferring.
- Review the press release dated November 8, 2021 (Exhibit 99.1) for details on INVO's immediate commercialization strategy.
- Monitor future filings for the impact of this transition on revenue recognition and operating expenses.